Rapamycin (Sirolimus) Monitoring Schedule: Labs & Exams

Print or save as PDFOpens the printable lab tracker and your print dialog. No sign-up.

What the label actually instructs

Rapamune is taken once daily, consistently with or without food, and the maintenance dose is adjusted to bring sirolimus trough concentrations into the target range [1]. At low-to-moderate immunologic risk the label describes a 6 mg loading dose on day 1 and 2 mg daily thereafter with cyclosporine and corticosteroids; at high immunologic risk, up to 15 mg on day 1 and 5 mg daily for the first 12 months [1]. LAM starts at 2 mg/day and is also adjusted to the target trough [1].

Sirolimus clears slowly. Mean terminal half-life was about 62 hours (SD 16) in stable renal transplant patients, and 91% of radioactivity was recovered in feces [1]. The label also warns that frequent dose changes based on non-steady-state concentrations can lead to overdosing or underdosing [1].

Trough levels: the one timetable the label gives

• The label says trough concentrations should be monitored at least 3 to 4 days after a loading dose [1].
• After a maintenance dose change, the label directs keeping the patient on the new dose for at least 7 to 14 days before the next adjustment with concentration monitoring [1].
• The label describes adjustment by simple proportion: new dose equals current dose multiplied by the target concentration divided by the current concentration [1]. A loading dose of 3 times the difference between the new and current maintenance dose can be added when troughs must rise, and the total given on any day should not exceed 40 mg [1].
• In whole blood, sirolimus is the major component and accounts for more than 90% of immunosuppressive activity; the whole-blood-to-plasma ratio is 36 [1].
• The label directs taking Rapamune 4 hours after cyclosporine, because cyclosporine increases sirolimus concentrations; when cyclosporine is withdrawn, higher sirolimus doses are needed to hold the same trough [1].

Lipids: the check the label names for every patient

Increased cholesterol and triglycerides requiring treatment occurred more often with Rapamune than with azathioprine or placebo in the label's renal transplant studies [1]. In Study 2, hypertriglyceridemia was reported in 45% of patients on 2 mg/day, 57% on 5 mg/day and 23% on placebo, and hypercholesterolemia in 43%, 46% and 23% [1]. The label states that any patient given Rapamune should be monitored for hyperlipidemia and that, if it is detected, diet, exercise and lipid-lowering agents should be started as outlined by the National Cholesterol Education Program guidelines [1]. Up to 90% of trial patients needed anti-lipid treatment, and despite that up to 50% still had fasting cholesterol above 240 mg/dL and triglycerides above target [1].

A small mechanistic study gives a sense of the size of the shift. Six renal transplant recipients on cyclosporine and prednisone, chosen because they had previously developed hyperlipidemia on sirolimus, took 10 mg/day for up to 42 days; mean total cholesterol rose from 214 to 322 mg/dL (50%, range 25 to 92) and mean triglycerides from 227 to 432 mg/dL (95%, range 9 to 254). The authors described these changes as repeatable, reversible and dose dependent [4].

Blood counts

In Study 2, thrombocytopenia was reported in 14% of patients on 2 mg/day, 30% on 5 mg/day and 9% on placebo; anemia was reported in 23%, 33% and 21% [1]. Leukopenia sits in the label's band of reactions reported in 3% to less than 20% of patients [1]. The label notes that adverse reactions were dose- and concentration-dependent and that 2 mg/day had a better overall safety profile than 5 mg/day [1]. These are transplant-dose rates, not rates for the low intermittent doses used in longevity trials.

Red-cell indices also moved at a low daily dose. In a pilot trial of 25 generally healthy adults aged 70 to 95 randomized to rapamycin 1 mg daily or placebo, 11 rapamycin and 14 placebo participants completed at least 8 weeks; the rapamycin group had statistically significant decreases in hemoglobin, hematocrit, red cell count, RDW, MCV and MCH, along with one case of facial rash, one of stomatitis and two reports of gastrointestinal issues [3].

Creatinine and proteinuria

The label lists a decline in renal function when Rapamune is combined long term with cyclosporine, proteinuria, and an increased risk of calcineurin-inhibitor-associated hemolytic uremic syndrome, thrombotic thrombocytopenic purpura and thrombotic microangiopathy [1]. In Study 2, increased creatinine was reported in 39% of patients on 2 mg/day, 40% on 5 mg/day and 38% on placebo [1].

Liver tests and hepatic dosing

Rapamune is metabolized in the intestinal wall and liver by CYP3A4, with P-glycoprotein counter-transport back into the gut lumen [1]. Hepatic impairment raises exposure: AUC increased by 43% in mild, 94% in moderate and 189% in severe impairment, and the label reduces the maintenance dose by about one third in mild-to-moderate impairment and about one half in severe impairment [1]. The dosing section directs reducing the maintenance dose in patients with hepatic impairment [1].

Glucose and new-onset diabetes

Sirolimus use at the time of transplantation was independently associated with new-onset diabetes in an analysis of 20,124 adult first kidney transplant recipients without diabetes. Compared with cyclosporine plus an antimetabolite, adjusted hazard ratios were 1.61 for sirolimus with cyclosporine, 1.66 with tacrolimus and 1.36 with an antimetabolite [5]. In mice, chronic rapamycin impaired glucose tolerance and insulin action by disrupting mTORC2, the complex required for insulin-mediated suppression of hepatic gluconeogenesis [6]. The mouse work describes a mechanism, not a human monitoring interval.

Checks the bloodwork does not replace

The boxed warning covers increased susceptibility to infection and the possible development of lymphoma and other malignancies, particularly of the skin [1]. Lymphoma and lymphoproliferative disease were reported in 0.7% to 3.2% of Rapamune-treated patients versus 0.6% to 0.8% of azathioprine and placebo controls in Studies 1 and 2 [1]. The label also lists fluid accumulation and impaired or delayed wound healing, hypersensitivity reactions including angioedema (with higher risk when ACE inhibitors are used together), and interstitial lung disease as risks that are separate from the routine laboratory findings discussed above [1].

Skin cancer is one outcome a transplant trial has tested directly. In a multicenter trial, 64 transplant recipients with at least one cutaneous squamous-cell carcinoma were switched from a calcineurin inhibitor to sirolimus and 56 stayed on their regimen; new squamous-cell carcinomas developed in 22% versus 39% (relative risk 0.56, 95% CI 0.32 to 0.98; median time to onset 15 versus 7 months), with 60 serious adverse events in the sirolimus group versus 14 in the calcineurin-inhibitor group and 23% discontinuing sirolimus because of adverse events [7].

Interactions that change the numbers on the report

Sirolimus is a substrate of both CYP3A4 and P-glycoprotein, so inhibitors raise its concentration and inducers lower it [1]. The label says to avoid strong inducers (rifampin, rifabutin) and strong inhibitors (ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, clarithromycin) and to consider alternatives with less interaction potential [1]. For weak or moderate modulators the label says to exercise caution and consider adjusting the dose, listing diltiazem, fluconazole, verapamil, clotrimazole, and HIV or hepatitis C protease inhibitors as drugs that could increase sirolimus concentrations and carbamazepine, phenobarbital, phenytoin, rifapentine and St. John's wort as drugs that could decrease them [1]. Cannabidiol can raise sirolimus levels, and the label says to monitor closely and consider a Rapamune dose reduction [1]. The label says grapefruit juice must not be taken with Rapamune or used to dilute it [1].

Monitoring in low-dose off-label use

The label specifies trough-monitoring timing for dose changes and says patients receiving Rapamune should be monitored for hyperlipidemia [1]. Those instructions were written for transplant and LAM dosing. In the 48-week PEARL trial of once-weekly compounded rapamycin, adverse events and blood biomarkers were monitored [2]. The 25-person Kraig pilot of 1 mg daily monitored CBC, metabolic panels, HbA1c and oral glucose tolerance tests, along with cognitive and physical-performance measures [3].

Off-label low-dose use

There is no FDA-approved indication for aging, longevity or healthspan; the labelled uses are renal transplant rejection prophylaxis and LAM [1]. The 48-week PEARL trial (NCT04488601) gave healthy, normative-aging adults placebo or 5 mg or 10 mg of compounded rapamycin once weekly; adverse and serious adverse events were similar across groups, biomarkers stayed within normal ranges, visceral adiposity did not change, and the authors concluded that low-dose intermittent rapamycin was relatively safe over 48 weeks with efficacy not established [2]. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before they are marketed [8].